Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News JOHNSON & JOHNSON JNJ

Healthcare Biotechnology
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:JNJ)

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years

Business Wire 3 days ago

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease

PR Newswire 3 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

PR Newswire 3 days ago

Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation

PR Newswire 5 days ago

Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

Canada NewsWire 13 days ago

Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

PR Newswire 13 days ago

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

PR Newswire March 8, 2025

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Business Wire March 5, 2025

Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

Business Wire March 4, 2025
View More News ››

Opinion & Analysis (NYSE:JNJ)

The ProMIS of an Alzheimer's cure

The Life Sciences Report May 4, 2017

Investment in cell and gene therapies ramps up

The Life Sciences Report June 8, 2016

What Andy Grove and Michael Milken have taught us about prostate cancer

The Life Sciences Report April 20, 2016

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

Bearish On Bucks? Try This ETF

Benzinga.com  September 18, 2015

Eight iconic American companies that have been hurt by the strong dollar

Stockhouse Editorial September 10, 2015
View More Opinion ››

Bullboard Posts (NYSE:JNJ)

Neutral Recommendation Issued On JNJ By Johnson Rice

News; $JNJ Neutral Recommendation Issued On JNJ By Johnson Rice2025-01-22 03:15:04 ET Johnson Rice analyst issues NEUTRAL recommendation...
whytestocks - January 22, 2025

Rate cuts are pulling attention toward growth sectors

Hi J&J followers!   Rate cuts are pulling attention toward growth sectors, but what does this mean for healthcare giants...
cmarketinsights - December 10, 2024

JNJ: Strong Pharma Growth, But Legal Risks Remain ⚠️

JNJ’s pharma division is crushing it, with big hits like Imbruvica and Darzalex driving revenue. But the ongoing legal battles—especially...
SmartBull65 - December 3, 2024

$JNJ Steady but Slow: Where’s the Spark?

Johnson & Johnson ($JNJ) is a safe, steady name but lacks growth oomph. Diagnostic biotech firms, like MYNZ, bring the innovation...
WealthLine48 - November 26, 2024

JNJ's Flatline: Buy Opportunity?

I’ve been watching JNJ, and despite its steady dividends, the stock is stuck around $155. Promising drug trials like their psoriasis...
SmartBull65 - November 24, 2024

Is $JNJ Ready to Bounce Back?

Just checked the chart on $JNJ—looks like it’s been consolidating for a minute. Could see a reversal soon if support holds at $152. Also...
TradeDriver718 - November 22, 2024
View more Bullboard ››

Geodrill Limited

Geodrill Limited

Geodrill Limited is an Isle of Man-based exploration drilling company operating in Africa and South America. The Company ...
View More »